Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo

FASEB Journal

Volumn 12, Issue 15, 1998, Pages 1777-1783

  Praticò, Domenico ^a   Lee, Virginia M Y ^a   Trojanowski, John Q ^a   Rokach, Joshua ^b   Fitzgerald, Garret A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Florida Institute of Technology   (United States)

^c 153 Johnson Pavilion ^*  (United States)

Author keywords

Neurofibrillary tangles; Oxidative stress; Schizophrenia; Temporal lobes

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; ISOPROSTANE; PROSTAGLANDIN SYNTHASE; 8,12 ISO ISOPROSTANE F2ALPHA III; 8,12 ISO ISOPROSTANE F2ALPHA VI; 8,12-ISO-ISOPROSTANE F2ALPHA-III; 8,12-ISO-ISOPROSTANE F2ALPHA-VI; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; FEMALE; FRONTAL LOBE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; TEMPORAL LOBE; BRAIN LEVEL; CEREBELLUM; CEREBROSPINAL FLUID; CHEMISTRY; COMPARATIVE STUDY; STEREOISOMERISM;

EPICOCCUM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN CHEMISTRY; CEREBELLUM; CEREBROSPINAL FLUID; DINOPROST; FEMALE; FRONTAL LOBE; HUMANS; LIPID PEROXIDATION; MALE; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; PARKINSON DISEASE; SCHIZOPHRENIA; STEREOISOMERISM; TEMPORAL LOBE;

EID: 0032238783     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.12.15.1777     Document Type: Article

References (51)

1. Morrison-Bogorad, M., Weiner, M. F., Rosenberg, R. N., Bigio, E., and White, C. L. (1997) In: The Molecular and Genetic Basis of Neurological Disease, 2nd Ed (Prusiner, S. B., Rosenberg, R. N., DiMauro, S., and Barchi, R. L., eds) pp. 581-600, Butterworth-Heinemann Press, Boston, Massachusetts
2. Van Duijn, C. (1996) Epidemiology of dementias: recent developments and new approaches. J. Neurol. Neurosurg. Psychiatry 60, 478-488
3. Goedert, M., Trojanowski, J. Q., and Lee, V. M.-Y. (1997) Tau Neurofibrillary Pathology of Alzheimer's disease. In: The Molecular and Genetic Basis of Neurological Disease, 2nd Ed (Prusiner, S. B., Rosenberg, R. N., DiMauro, S., and Barchi, R. L., eds) pp. 613-628, Buttenvorth Heineman Press, Boston, Massachusetts
4. Selkoe, D. J . (1997) Alzheimer's disease: genotypes, phenotype, and treatment. Science 275, 630-631
5. Hardy, J. (1997) The Alzheimer's family of diseases: many etiologies, one pathogenesis? Proc. Natl. Acad. Sci. USA 94, 2095-2097
6. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M, Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., and Younkin, S . (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870
7. Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Liederburg, I., and Rydel, R. E. (1992) β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. Neuroscience 12, 376-389
8. Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B. A. (1995) βAmyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888
9. Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (London) 380, 168-171
10. Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994) Hydrogen peroxide mediates amyloid protein toxicity. Cell 77, 817-827
11. Gotz, M. E., Kunig, G., Rieder, P., and Youdim, M. B. H. (1994) Oxidative stress: free radical production in neuronal degeneration. Pharmacol. Ther. 63, 37-122
12. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Rad. Biol. Med. 23, 134-147
13. Gutteridge. J. M. G., and Halliwell, B. (1990) The measurement and mechanism of Hpid peroxidation in biological systems . Trends Biochem. Sci. 15, 129-1365
14. Subbarao, K. V., Richardson, J. S., and Ang, L. C. (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55, 342-345
15. Palmer, A. M., and Burns, M. A. (1994) Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645, 338-342
16. Lovell, M. A., Ehmann, W. D., Rutler, S. M., and Markesbery, W. R. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601
17. Balazs, L., and Leon, M. (1994) Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem. Res. 19, 1131-1137
18. Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., and Halliwell, B. (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease.J. Neurochem. 68, 2061-2069
19. Hayn, M., Kremser, K., Singewald, N., Cairns, N., Nemethova, M., Lubec, B., and Lubec, G. (1996) Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci. 59, 537-544
20. Montine, K. S., Kim, P. J., Olson, S. J., Markesbery, W. R., and Montine, T. J. (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease.J. Neuropathol. Exp. Neurol. 56, 866-871
21. Sayre, L. M., Zelasko, D. A., Harris, P. L. R., Perry, G., Salomon, R. G., and Smith, M. A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092-2097
22. Lovell, M. A., Ehmann, W. D., Mattson, M. P., and Markesbery, W. R. (1997) Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging 18, 457-461
23. Awad, J. A., Morrow, J. D., Takahashi, K., and Roberts, I., J. (1993) Identification of non-cyclooxygenase-derivedprostanoids (F2-isoprostanes) metabolites in human urine and plasma. J. Biol. Chem. 268, 4161-4169
24. Morrow, J. D., Awad.J. A., Boss, H. J., Blair, I. A., and Roberts, L. J. (1992) Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA 89, 10721-10725
25. 2α . J. Biol. Chem. 270, 9800-9808
26. 2α-I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA 95, 3449-3454
27. Rokach, J., Khanapure, S. P., Hwang, S.-W., Adiyaman, M., Lawson, J. A., FitzGerald, G. A. (1997) Nomenclature of isoprostanes: a proposal. Prostaglandins 54, 853-873
28. 2α by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxides symhase-2. J. Biol. Chem. 271, 8919-8924
29. Reilly, M., Delanty, N., Lawson, J. A., and FitzGerald, G. A. ( 1996) Modulation of oxidant stress in vivoin chronic cigarette smokers. Circulation 94, 19-25
30. 2α generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation 95, 2492-2499
31. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100, 2027-2034
32. 2α-isoprostanes in hypercholesterolemia. Circulation In press
33. Schmidt, M. L., Lee, V. M.-Y., and Trojanowski, J. Q. (1991) Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neuntes and neurophil threads. Lab. Invest. 64, 352-357
34. Arnold, S. E., Gur, R. E., Shapiro, R. M., Fisher, K. R., Moberg, P. J., Gibney, M. R., Gur, R. C., Blackwell, P., and Trojanowski, J. Q. (1995) Prospective clinico-pathologic studies of schizophrenia: accrual and assessment of patients. Am. J. Psych. 152, 731-737
35. Schmidt, M. L., Martin, J. A., Lee, V. M.-Y., and Trojanowski, J. Q. (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol. 91, 475-481
36. Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadman, E. R., Floyd, R. A., and Markesbery, W. R. (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 88, 10540-10543
37. Smith, M. A., Perry, G., Richey, P. L., Sayre, L. M., Anderson, V. E., Beal, M. F., and Kowall, N. (1996) Oxidative damage in Alzheimer's disease. Nature (London) 382, 120-121
38. Mecocci, P., MacGarvey, U., and Beal, M. F. (1994) Oxidative damage to mitochondrial DNA is increased in AJzheinier's disease. Ann. Neurol. 36, 747-751
39. Dyrks, T., Dyrks, E., Masters, C. L., and Beyrenther, K. (1993) Amyloidogeneicity of rodent and human βA4 sequences. FEBS Lett. 324, 231-236
40. Miyata, M., and Smith, J. D. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genet. 14, 55-61
41. 2-isoprostanes in vivo: indices of oxidant stress in aiherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 17, 2309-2315
42. Rokach, J., Khanapure, S. P., Hwang, S.-W., Adiyaman, M., Lawson, J. A., and FitzGerald, G. A. (1997) The isoprostanes: a perspective. Pro staglandins 54, 823-851
43. 2α in acute coronary angioplasty. Evidence for oxidant stress during coronary reperfusion in humans. Circulation 96, 3314-3320
44. Praticò, D., Tangirala, R. K., Rader, D. J., Rokach, J., and FitzGerald, G. A. (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nature Med. 4, 1189-1192
45. 2-alpha and related enzymes in post-mortem human brain. J. Neurochem. 43: 71-82
46. Frederikse, P. H., Garland, D., Zigler, J. S., and Piatigorsky, J. (1996) Oxidative stress increases production of β-amyloid precursor protein and β-amyloid (Aβ) in mammalian lenses, and Aβ has toxic effects on lens epithelial cells. J. Biol. Chem. 272, 10169-10174
47. Roberts, L. J., Mon tine, T. J., Markesbery, W. R., Tapper, A. R., Hardy, P., Chemtob, S., Dettbam, W. F., and Morrow, J. D. (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273: 13605-13612
48. Kaufmann, W. E., Andreasson, K. I., Isakson, P. C., and Worley, P. F. (1997) Cyclooxygenase and the central nervous system. Prostaglandins 54, 601-624
49. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632
50. McGeer, P. L., and Rogers, J. (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42, 447-449
51. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., and Thal, L. J. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336, 1216-1222